Abstract
Clinical investigations of adoptive therapy in solid tumors have primarily focused on CD8+ cells. A study by Hunder et al. is the first to demonstrate the significance of antigen-specific CD4+ T cells. An in vitro method was used to treat a patient with metastatic melanoma using autologous CD4+ cells against NY-ESO-1 (cancer and/or testis antigen 1). The successful adoptive transfer of antigen-specific CD4+ cells to a patient with metastatic melanoma is not only an important technical accomplishment but also provides increased understanding of tumor immunity. This report demonstrates an impressive persistence of adoptively transferred cells together with durability of clinical response. CD4+ T cells that target a particular antigen can augment T-cell responses to other tumor-associated targets. These observations underline the importance of ongoing research for effective, non-toxic immune therapies for cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hunder NN et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698–2703
Dudley ME and Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34: 524–531
June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466–1476
June CH (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117: 1204–1212
Du J et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565–576
Rosenberg SA et al. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299–308
Knutson KL and Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54: 721–728
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D Fisher is a Consultant for Novartis, Magen Biosciences and Source MDx. F Stephen Hodi is a non-paid Consultant for Bristol-Myers Squibb, Medinex Inc and Pfizer.
Rights and permissions
About this article
Cite this article
Hodi, F., Fisher, D. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Rev Clin Oncol 5, 696–697 (2008). https://doi.org/10.1038/ncponc1259
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1259